Why Now Daily.

Published

RSV Vaccines and Preventive Antibodies: Who They Are For

U.S. RSV prevention uses vaccines for recommended adults and during a defined window of pregnancy, plus long-acting antibodies for eligible infants and a small high-risk group entering a second season. FDA authorization and CDC recommendations are related but are not identical.

Timeline

  1. Before RSV season: Adults and families review age, risk, pregnancy timing, birth timing and local seasonality with a clinician.
  2. During weeks 32–36 of pregnancy: In most of the continental United States, eligible pregnant people receive Pfizer Abrysvo seasonally, usually September through January.
  3. At birth or before the first season: Eligible infants receive nirsevimab or clesrovimab, generally when maternal vaccination did not provide protection.

Respiratory syncytial virus can cause lower-respiratory disease, especially in infants and older or medically vulnerable adults. U.S. prevention now includes vaccines that prompt the recipient’s immune system to respond and long-acting monoclonal antibodies that directly provide an infant with passive protection. The products are not interchangeable, and being licensed by the FDA does not automatically mean CDC recommends every licensed age group in the same way. [1][2][3]

CDC currently recommends one dose of an FDA-licensed RSV vaccine for everyone age 75 or older and for adults ages 50 through 74 who have an increased risk of severe RSV. Risk can include chronic heart or lung disease, immune compromise, certain other conditions, frailty, and residence in a nursing home. This is not described as an annual vaccine at present; someone who already received a dose should not repeat it each season unless future guidance changes. [1][4]

FDA labels cover some younger adults at increased risk, including ages 18 through 59 for particular products, but CDC’s routine recommendation as reviewed here begins at age 50 for higher-risk adults. Product choice, precautions and timing should be discussed with a clinician. RSV vaccination can be given at any time of year, but CDC says late summer or early fall is the best timing for eligible adults who have not yet received a dose, before RSV usually begins spreading. [1][4][5]

For infant protection through pregnancy, CDC recommends one dose of Pfizer’s Abrysvo during 32 weeks 0 days through 36 weeks 6 days of pregnancy. In most of the continental United States, the seasonal window is September through January; timing differs in places with different RSV circulation. Abrysvo is the only RSV vaccine recommended during pregnancy. Most infants whose mother received it at least 14 days before birth do not also need an infant antibody. [2][6]

For babies younger than 8 months who are born during or entering their first RSV season, CDC recommends a long-acting antibody when the mother did not receive maternal RSV vaccine, the vaccination status is unknown, or birth occurred within 14 days after vaccination. Nirsevimab and clesrovimab are available for this first-season use. They are monoclonal antibodies, not vaccines: protection is immediate and temporary rather than generated through the baby’s own long-term immune response. [3][7][8]

A smaller group of children ages 8 through 19 months entering a second RSV season should receive nirsevimab because they remain at increased risk. CDC lists qualifying groups such as certain children with chronic lung disease of prematurity, severe immune compromise, severe cystic fibrosis, and American Indian or Alaska Native children. Clesrovimab is not approved or recommended for second-season use, and children 8 months or older without those risk factors generally should not receive an infant RSV antibody. [3][7]

The practical choice depends on age, risk, pregnancy dates, birth date, prior immunization and local seasonality. Bring the vaccination record to the obstetrician, pediatrician or adult clinician and verify the current CDC schedule because recommendations and products can change. Ask about contraindications and side effects using the relevant package insert. Prevention reduces severe disease risk but does not guarantee that infection cannot occur, so respiratory symptoms still deserve appropriate testing, supportive care and urgent evaluation for trouble breathing or dehydration. [1][2][3][5][8]

Sources

  1. CDC — RSV Vaccine Guidance for Adults
  2. CDC — RSV Vaccine Guidance for Pregnant Women
  3. CDC — RSV Immunization Guidance for Infants and Young Children
  4. CDC — Clinical Guidance for RSV Immunizations and Vaccines
  5. FDA — MRESVIA
  6. FDA — ABRYSVO
  7. CDC — Immunizations to Protect Infants
  8. FDA — Drug Trials Snapshot: ENFLONSIA (clesrovimab)

Related stories